| Name | Title | Contact Details |
|---|
The Institute for Athletic Medicine is a Chicago, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
ImmusanT, Inc is a biotechnology company focused on developing a treatment, and a set of diagnostic and monitoring tools to manage patients with Celiac disease.
Hydromer® is a leading global surface modification and coatings solutions provider. As a trusted partner to companies worldwide, our solutions add value to our clients products so that they can stand out in the marketplace. We are an innovation-driven, customer-centered organization with a focus on meeting our clients needs. Hydromer collaborates extensively with clients to deliver superior, customized polymer-based solutions. We create or modify coating formulations that adhere to a multitude of substrates and match the unique requirements and geometries of any device. We are a leader in developing coating formulas and processes that meet a market-driven need for greener, more sustainable solutions. We offer custom industrial and medical device coatings, contract coating services, customized coating equipment, contract manufacturing, and turnkey operations backed by outstanding teams of research and development, customer service, and tech support. Hydromer`s technologies enhance the value of our clients products by delivering lubricity, thromboresistance, anti-fogging, antimicrobial, and other properties. Our coatings aid in the manufacture of medical devices, aerospace components, cosmetics, and products in a variety of industries. We are an FDA, GMP/ISO 13485, and ISO 9001 production facility.
Peptimmune, Inc. is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body`s immune response. Celldex Therapeutics (NASDAQ: CLDX) was founded based on a fundamental scientific belief that harnessing the power of the immune system would break significant barriers in drug development for a host of devastating diseases. The Company`s pipeline is comprised of therapeutic antibodies, antibody drug conjugates, immune system modulators and vaccines that we believe have a higher probability of success because they are targeted to specific patient populations with high unmet medical need whose diseases express specific markers, including many underserved or completely un-served orphan indications. This has created a leading pipeline in immuno-oncology.